Trametinib Treatment for Complicated Vascular Anomalies
- Sponsor
- West China Hospital
- Study ID
- NCT07072403
- Phase
- PHASE1/PHASE2
- Status
- Active Not Recruiting
Conditions
- Vascular Anomalies
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trametinib tablet — DRUGDrug is supplied in 0.5 mg and 2 mg tablets
Study Details
Complicated vascular anomalies have diverse etiologies and variable clinical manifestations, and no standardized treatment protocol has been established. Since most patients present with diffuse lesions that are difficult to resect surgically, identifying effective therapeutic strategies is of critical importance. This study aims to evaluate the safety and efficacy of systemic trametinib therapy in patients with complicated vascular anomalies.
Key Dates
- Start date
- Jul 7, 2025
- Status verified
- Jul 2025
- Primary completion
- Jul 1, 2027
- Completion
- Sep 1, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Oral TrametinibPatients will receive oral trametinib once daily
Primary Outcome Measure
The proportion of patients achieving an objective response at month 12 [ Time Frame: 12 months ]
Related Studies
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)PHASE2 · Recruiting · Relay Therapeutics, Inc. · Phoenix, Arizona